Overview

* Intensity Therapeutics ( INTS ) Q3 net loss narrows to $2.7 mln from $3.5 mln last year

* Company raised $13.6 mln since Q3 start, extending cash runway to Q1 2027

* Research and development expenses decreased due to lower clinical trial costs

Outlook

* Company plans to reinitiate INVINCIBLE-4 Study enrollment in Q1 2026

* Company aims to restart INVINCIBLE-3 Study enrollment once funding is secured

* Cash runway extended until end of Q1 2027

Result Drivers

* CLINICAL TRIAL EXPENSES - Trial expenses fell $0.4 mln due to lower INVINCIBLE-3 study costs, helping lower overall R&D costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Basic -$0.06

EPS

Q3 -$2.73

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for Intensity Therapeutics Inc ( INTS ) is $3.00, about 81% above its November 5 closing price of $0.57

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)